Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13

Kazimierz Groen; Fredrik H. Schjesvold; Bronno van der Holt; Mark-David Levin; Maarten R. Seefat; Markus Hansson; Maria B. L. Leys; Josien C. Regelink; Anders Waage; Damian Szatkowski; Per Axelsson; Trung Hieu Do; Asta Svirskaite; Ellen van der Spek; Einar Haukas; Dorota Knut-Bojanowska; Paula F. Ypma; Cecilie H. Blimark; Ulf-Henrik Mellqvist; Niels W. C. J. van de Donk; Pieter Sonneveld; Anja Klostergaard; Annette J. Vangsted; Niels Abildgaard; Sonja Zweegman

doi:https://doi.org/10.1097/HS9.0000000000000940

Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13

Kazimierz Groen, Fredrik H. Schjesvold, Bronno van der Holt, Mark-David Levin, Maarten R. Seefat, Markus Hansson, Maria B. L. Leys, Josien C. Regelink, Anders Waage, Damian Szatkowski, Per Axelsson, Trung Hieu Do, Asta Svirskaite, Ellen van der Spek, Einar Haukas, Dorota Knut-Bojanowska, Paula F. Ypma, Cecilie H. Blimark, Ulf-Henrik Mellqvist, Niels W. C. J. van de DonkPieter Sonneveld, Anja Klostergaard, Annette J. Vangsted, Niels Abildgaard, Sonja Zweegman

Research output: Contribution to journal › Letter › Academic › peer-review

Original language	English
Pages (from-to)	E940
Journal	HemaSphere
Volume	7
Issue number	9
DOIs	https://doi.org/10.1097/HS9.0000000000000940
Publication status	Published - 30 Sept 2023

Access to Document

https://doi.org/10.1097/HS9.0000000000000940

Cite this

Groen, K., Schjesvold, F. H., van der Holt, B., Levin, M.-D., Seefat, M. R., Hansson, M., Leys, M. B. L., Regelink, J. C., Waage, A., Szatkowski, D., Axelsson, P., Hieu Do, T., Svirskaite, A., van der Spek, E., Haukas, E., Knut-Bojanowska, D., Ypma, P. F., Blimark, C. H., Mellqvist, U.-H., ... Zweegman, S. (2023). Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13. HemaSphere, 7(9), E940. https://doi.org/10.1097/HS9.0000000000000940

@article{56fcae50b6cf4f21aa39abef41678ecb,

title = "Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13",

author = "Kazimierz Groen and Schjesvold, {Fredrik H.} and {van der Holt}, Bronno and Mark-David Levin and Seefat, {Maarten R.} and Markus Hansson and Leys, {Maria B. L.} and Regelink, {Josien C.} and Anders Waage and Damian Szatkowski and Per Axelsson and {Hieu Do}, Trung and Asta Svirskaite and {van der Spek}, Ellen and Einar Haukas and Dorota Knut-Bojanowska and Ypma, {Paula F.} and Blimark, {Cecilie H.} and Ulf-Henrik Mellqvist and {van de Donk}, {Niels W. C. J.} and Pieter Sonneveld and Anja Klostergaard and Vangsted, {Annette J.} and Niels Abildgaard and Sonja Zweegman",

note = "Funding Information: This study had partial research funding from Takeda Pharmaceutical Company Limited.",

year = "2023",

month = sep,

day = "30",

doi = "https://doi.org/10.1097/HS9.0000000000000940",

language = "English",

volume = "7",

pages = "E940",

journal = "HemaSphere",

issn = "2572-9241",

publisher = "Wolters Kluwer Health",

number = "9",

}

Groen, K, Schjesvold, FH, van der Holt, B, Levin, M-D, Seefat, MR, Hansson, M, Leys, MBL, Regelink, JC, Waage, A, Szatkowski, D, Axelsson, P, Hieu Do, T, Svirskaite, A, van der Spek, E, Haukas, E, Knut-Bojanowska, D, Ypma, PF, Blimark, CH, Mellqvist, U-H, van de Donk, NWCJ , Sonneveld, P, Klostergaard, A, Vangsted, AJ, Abildgaard, N & Zweegman, S 2023, 'Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13', HemaSphere, vol. 7, no. 9, pp. E940. https://doi.org/10.1097/HS9.0000000000000940

Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13. / Groen, Kazimierz; Schjesvold, Fredrik H.; van der Holt, Bronno et al.
In: HemaSphere, Vol. 7, No. 9, 30.09.2023, p. E940.

Research output: Contribution to journal › Letter › Academic › peer-review

TY - JOUR

T1 - Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients

T2 - Long-term Results of HOVON-126/NMSG 21.13

AU - Groen, Kazimierz

AU - Schjesvold, Fredrik H.

AU - van der Holt, Bronno

AU - Levin, Mark-David

AU - Seefat, Maarten R.

AU - Hansson, Markus

AU - Leys, Maria B. L.

AU - Regelink, Josien C.

AU - Waage, Anders

AU - Szatkowski, Damian

AU - Axelsson, Per

AU - Hieu Do, Trung

AU - Svirskaite, Asta

AU - van der Spek, Ellen

AU - Haukas, Einar

AU - Knut-Bojanowska, Dorota

AU - Ypma, Paula F.

AU - Blimark, Cecilie H.

AU - Mellqvist, Ulf-Henrik

AU - van de Donk, Niels W. C. J.

AU - Sonneveld, Pieter

AU - Klostergaard, Anja

AU - Vangsted, Annette J.

AU - Abildgaard, Niels

AU - Zweegman, Sonja

N1 - Funding Information: This study had partial research funding from Takeda Pharmaceutical Company Limited.

PY - 2023/9/30

Y1 - 2023/9/30

UR - http://www.scopus.com/inward/record.url?scp=85171177792&partnerID=8YFLogxK

U2 - https://doi.org/10.1097/HS9.0000000000000940

DO - https://doi.org/10.1097/HS9.0000000000000940

M3 - Letter

C2 - 37663673

SN - 2572-9241

VL - 7

SP - E940

JO - HemaSphere

JF - HemaSphere

IS - 9

ER -

Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13

Access to Document

Other files and links

Cite this